Category Innovation/ R&D

High-Level UN Initiative On Global Public Health Gap Holds Landmark Hearing

An initiative of the United Nations secretary general yesterday gathered what could be described as an assembly of many of the world’s best thinkers and practitioners on public health and intellectual property rights. Industry, activists, academics, international organisations, and possibly some governments poured out their views for nearly seven hours – at times coming to tears and tension – shepherded by an astute moderator, as they responded to the call to take a longstanding debate on medicines access and high prices to a breakthrough.

WHO Welcomes UN Secretary-General’s High-Level Panel, Offers Suggestions

The World Health Organization has provided a list of suggestions to the United Nations Secretary General’s High-Level Panel on Access to Medicines, highlighting WHO activities in this area and making suggestions on areas the WHO has not yet been able to complete. It also describes several new proposals by WHO, including a global “fair pricing forum,” a pooled health product R&D fund, and a global antibiotic research and development facility.

UN Global Dialogue On Innovation And Access To Medicines This Week

The United Nations Secretary General’s High-Level Panel on Access to Medicines is holding a global dialogue this month, attended by governments, civil society, industry and academia, to discuss potential solutions to promote innovation and at the same time increase access to medicines. The first public dialogue session is this week, on 10 March in London.

TRIPS Council: Differing Views On IP Education; New Database Project Launched

Discussions on the worth of intellectual property for innovation and development have been a recurring agenda item during recent meetings of the World Trade Organization committee on intellectual property. This week, education and how it can raise awareness of IP was discussed with WTO members presenting their national experiences, and some developing countries warning against colluding IP and innovation.

Alleged R&D Costs: Not A Transparent Driver Of Drug Prices

Whether laws enforcing transparency on costs would help curb extortionate drug prices in today’s world is hardly predictable now that pharma companies and their allies are lobbying governments to scupper any rules that would require them to disclose the real R&D costs and profits of their medicines and the rationale for charging what they do, writes Daniele Dionisio.

European Patents Rising; EPO President Denies Retirement Package

BRUSSELS -- Patents applications are on the rise in Europe the European Patent Office President Benoît Battistelli said today, with half of the applications coming from European inventors. The United States led followed by Germany, and Japan, and China showing a strong growth. The EPO president also announced the signature of an agreement with one trade union against a background of social unrest in the organisation.

IEEE Patent Policy Changes Seek To Put Brakes On Surging Litigation

Intense debate, reignited by a 2012 International Telecommunication Union roundtable on rampant patent litigation and the “innovation-stifling” use of intellectual property, together with the growing lack of standards bodies' patent policies, prompted the IEEE Standards Association (IEEE) last year to revisit parts of its patent policy that had been causing some concerns, Managing Director Konstantinos Karachalios said at a 17 February Oxfirst webinar.

The changes aim to clear up some ambiguities. Perhaps predictably, however, some pushback has arisen among industries affected by the change.

Uganda In Clinical Trials For Ebola Vaccine

KAMPALA, Uganda -- An Ebola vaccine trial is underway in Uganda, as the global search for an effective vaccine continues. The vaccine candidate was co-developed by the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), and GlaxoSmithKline (GSK), a United Kingdom-based pharmaceutical company.